Good MorningEquity markets could be volatile on Thursday following NVIDIA's blowout earnings report. The bar was set high, and NVIDIA blew right past it, producing more than 120% YoY revenue growth and widening margin. The bigger news is that demand for its data center and networking products remains strong, leading to better-than-expected guidance. The problem is that as high as the bar was set, the market hoped for another blowout and moved lower on the news. In this environment, NVIDIA could remain range-bound for the foreseeable future.
Volatility could persist through the end of the week. The July read of the PCE price index is due on Friday ahead of a three-day weekend and is expected to accelerate. Accelerating inflation is contrary to the idea of falling interest rates and will be a negative for stocks. As it is, the market is banking on a rate cut in September and three by year's end, which may be too many too soon. Featured: Strange Options Secret (NOT Day Trading!) (Monument Traders Alliance) 
|
Markets | | |
Most stock investors suffer from tunnel vision, as most of their capital is tied up with individual stocks or index funds, and they believe that any risk or reward will be driven by price changes within them. However, stocks are only one cog in the financial market machine that moves through asset... Read the Full Story |
|
From Our PartnersA radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites.
And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. | | | | One company holds a near-total monopoly on it. |
|
Markets | | | Investor Warren Buffett's company has unloaded more of its Bank of America stake, selling nearly 25 million shares worth almost $1 billion over the past week.Berkshire Hathaway has steadily sold off 116 million Bank of America shares since July. But it still controls nearly 12% of the stock in the b... Read the Full Story |
|
Markets | | | Stocks on Wall Street closed lower Wednesday as a pullback in big technology companies outweighed gains elsewhere in the market.The S&P 500 fell 0.6%, weighed down by drops in Nvidia, Apple, Microsoft and Amazon. About 56% of the stocks in the benchmark index finished in the red. Tech sector sto... Read the Full Story |
|
From Our PartnersEarlier this year President Biden signed the death warrant for America…
Executive Order 14067 will essentially cancel your money.
You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar... | | | | Get your free information kit NOW, before it's too late. |
|
Markets | | |
Earnings results from the Q2 reporting cycle are mixed. Some are good, and some are bad. The takeaway is that some are good, and the analysts reward those companies with upgrades and price target revisions to increase their share prices. That is the focus of this article: the three stocks the most... Read the Full Story |
|
Markets | | |
When investors think of commodities and their long-term demand cycles, gold and silver often come to mind as investments that can take advantage of the market's long-term upside. However, the answer to aligning a portfolio with a long-term winning commodity involves figuring out which leading econ... Read the Full Story |
|
From Our PartnersLately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks.
It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives.
But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars.
And here's the good news. | | | | Register For The Webinar To Discover |
|
Markets | | |
Chewy’s (NYSE: CHWY) stock price has struggled since the peaks set in 2020 because it could not sustain the wicked-hot growth pace driven by pandemic spending and stimulus measures. Today’s takeaway is that the market for Chewy stock has normalized, and its business turned a corner i... Read the Full Story |
|
Stocks | | | A late-afternoon slide by some Big Tech companies cut into Wall Street’s gains Thursday, leading to a mixed finish for U.S. stock indexes.The S&P 500 ended flat after giving up an earlier gain of nearly 1%. The benchmark index is about 1.3% away from its record set in July.The Dow Jones Industri... Read the Full Story |
|
Markets | | | Nvidia may have exceeded Wall Street estimates as its profit jumped — buffeted by the chipmaking dominance that has cemented Nvidia’s place as the poster child of the artificial intelligence boom — but investors seemed less than impressed Read the Full Story |
|
Markets | | | Nvidia has once again turned out quarterly results that easily exceeded Wall Street's forecast s. The company has seen soaring demand for its semiconductors, which are used to power artificial intelligence applications. Revenue more than doubled in the latest quarter from the same period a year earl... Read the Full Story |
|
Markets | | |
Kohl's Corporation (NYSE: KSS) finds itself navigating choppy waters in the turbulent sea of the retail sector. The renowned omnichannel retailer, known for its value-driven offerings and loyal customer base, recently released its second-quarter fiscal year 2024 earnings report. Kohl’s earni... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. | | View Today's Stock Pick |
|
